Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

ABSTRACT:

Opinion statement

With the introduction of tyrosine kinase inhibitors (TKIs) in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), the prognosis of patients has improved dramatically. Currently, the standard of care in the frontline setting for fit patients is TKI in combination with chemotherapy. Age-adjusted chemotherapy or corticosteroids alone have been used with TKIs in elderly patients with comorbidities with modest long-term benefit. The primary goal of treatment is the achievement of early deep molecular remission as the achievement of complete molecular remission (CMR) at 3 months has been demonstrated to be predictive of higher long-term survival. The probability of attaining this goal by a more potent TKIs like dasatinib or ponatin

SUBMITTER: Abou Dalle I 

PROVIDER: S-EPMC10231844 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature